Insulin degludec: a significant advancement in ultralong-acting Basal insulin.

ABSTRACT: This editorial discusses a novel basal insulin analog, insulin degludec. It describes the limitations of existing basal insulins, and builds the case for a better analog. The editorial discusses the evidence to support the efficacy, safety, tolerability, and flexibility of degludec, and assesses its utility as part of a person-centered approach to diabetes management.

SUBMITTER: Kalra S 

PROVIDER: S-EPMC3889334 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature